Four distinct metabolic profiles identified among 405,023 participants link directly to varying cancer risks and trajectories, according to research published on Friday.
The study examined data from the UK Biobank cohort published in the revue « Nature Communications », where 54.1% of the participants were women and the average age reached 56.4 years.
During the follow-up period, 60,909 participants, representing about 15% of the cohort, developed a first cancer. Among them, 5,632 subsequently presented multiple distinct primary cancers.
The analysis focused on 25 endocrine, nutritional, and metabolic diseases to determine their associations with the onset of an initial cancer, the development of multiple primary cancers, and mortality. The scientific team identified four major profiles. The first profile, designated C1, is mainly characterized by iron metabolism disorders and iron deficiencies.
The second profile, C2, is dominated by type 2 diabetes. The third profile, C3, primarily groups anomalies of lipid and lipoprotein metabolism. Finally, the fourth profile, C4, is associated with a predominance of osteoporosis. These categories were established based on associations observed among several metabolic diseases rather than from a simple blood test allowing automatic classification of each individual.
The investigation reveals that these different profiles do not exhibit the same associations with cancer incidence and progression. Certain disorders may be more closely linked to specific cancer locations, while others appear associated with more complex trajectories. Researchers studied interactions among multiple metabolic conditions present in a single individual to better understand why people with seemingly comparable health problems can experience different clinical evolutions.
The UK Biobank cohort comprises half a million volunteer participants recruited across Great Britain between 2006 and 2010. This large-scale resource is designed to track health outcomes over at least 30 years, providing a comprehensive, de-identified database that includes biological samples, physical measurements, and lifestyle data. By integrating these diverse datasets, the organization enables researchers to study the early stages of disease development.
Serving as an unprecedented open-access database, UK Biobank holds more than 10,000 variables on its participants, including the world’s largest human genome sequencing, proteomic, and imaging projects. This depth of information allows scientists to investigate complex interactions between metabolic conditions and cancer, facilitating large-scale research into the prevention, diagnosis, and treatment of various health conditions.
To deepen their findings, the scientists examined proteins and metabolites present in the body to identify biological mechanisms potentially contributing to the observed links between metabolic disorders and cancer. They also developed a predictive model utilizing deep learning and multiple categories of medical data to improve risk estimation and personalized prevention strategies, although additional research remains necessary to confirm their clinical applicability.
Keep reading